Wolfgang Sadée
Wolfgang Sadée has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Danxin Wang
Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA
7 shared publications J. Mark Quillan
From the ‡Department of Biopharmaceutical Sciences and Pharmaceutical Chemistry and the Wheeler Center for Neurobiology of Addiction, University of California, San Francisco, California 94143-0446 and the §Department of Chemistry, University of California, Berkeley, California 94721
2 shared publications- Julie L. Lucas
MRIGlobal
2 shared publications Richard C. Graul
Incyte Genomics, Palo Alto, CA 94304, USA
2 shared publications- Carsten Uhd Nielsen
Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55 DK-5230, Odense M, Denmark
1 shared publication Christopher K Surratt
1 shared publication
Latest Publications
- Open Access
- 4 January 2002
- Published by Wiley in Journal of Neurochemistry
- Vol. 75 (2) , 763-771
Calmodulin Regulation of Basal and Agonist-Stimulated G Protein Coupling by the μ-Opioid Receptor (OP3) in Morphine-Pretreated Cell
- 4 January 2002
- Published by Wiley in Journal of Neurochemistry
- Vol. 75 (2) , 763-771
Open AccessCalmodulin Regulation of Basal and Agonist-Stimulated G Protein Coupling by the μ-Opioid Receptor (OP3) in Morphine-Pretreated Cell
- 1 September 2001
- Published by Springer Nature in AAPS PharmSci
- Vol. 3 (3) , 54-80
Genetic variations in human G protein-coupled receptors: Implications for drug therapy
- 1 September 2001
- Published by Springer Nature in AAPS PharmSci
- Vol. 3 (3) , 54-80
Genetic variations in human G protein-coupled receptors: Implications for drug therapy
- Open Access
- 1 September 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (37) , 34624-34630
Single Nucleotide Polymorphisms in the Human μ Opioid Receptor Gene Alter Basal G Protein Coupling and Calmodulin Binding
- 1 September 2001
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 276 (37) , 34624-34630
Open AccessSingle Nucleotide Polymorphisms in the Human μ Opioid Receptor Gene Alter Basal G Protein Coupling and Calmodulin Binding
- 15 June 2001
- Published by Wiley in Journal of Neurochemistry
- Vol. 77 (6) , 1590-1600
Inverse agonists and neutral antagonists at µ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence
The µ opioid receptor, MOR, displays spontaneous agonist‐independent (basal) G protein coupling in vitro. To determine whether basal MOR signaling contributes to narcotic dependence, antagonists were tested for intrinsic effects on basal MOR signaling in vitro and in vivo, before and after morphine pretreatment. Intrinsic effects of MOR ligands were tested by measuring GTPγS binding to cell membranes and cAMP levels in intact cells. β‐CNA, C‐CAM, BNTX, and nalmefene were identified as inverse agonists (suppressing basal MOR signaling). Naloxone and naltrexone were neutral antagonists (not affecting basal signaling) in untreated cells, whereas inverse agonistic effects became apparent only after morphine pretreatment. In contrast, 6α‐ and 6β‐naltrexol and ‐naloxol, and 6β‐naltrexamine were neutral antagonists regardless of morphine pretreatment. In an acute and chronic mouse model of morphine‐induced dependence, 6β‐naltrexol caused significantly reduced withdrawal jumping compared to naloxone and naltrexone, at doses effective in blocking morphine antinociception. This supports the hypothesis that naloxone‐induced withdrawal symptoms result at least in part from suppression of basal signaling activity of MOR in morphine‐dependent animals. Neutral antagonists have promise in treatment of narcotic addiction.
- 15 June 2001
- Published by Wiley in Journal of Neurochemistry
- Vol. 77 (6) , 1590-1600
Inverse agonists and neutral antagonists at µ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence
The µ opioid receptor, MOR, displays spontaneous agonist‐independent (basal) G protein coupling in vitro. To determine whether basal MOR signaling contributes to narcotic dependence, antagonists were tested for intrinsic effects on basal MOR signaling in vitro and in vivo, before and after morphine pretreatment. Intrinsic effects of MOR ligands were tested by measuring GTPγS binding to cell membranes and cAMP levels in intact cells. β‐CNA, C‐CAM, BNTX, and nalmefene were identified as inverse agonists (suppressing basal MOR signaling). Naloxone and naltrexone were neutral antagonists (not affecting basal signaling) in untreated cells, whereas inverse agonistic effects became apparent only after morphine pretreatment. In contrast, 6α‐ and 6β‐naltrexol and ‐naloxol, and 6β‐naltrexamine were neutral antagonists regardless of morphine pretreatment. In an acute and chronic mouse model of morphine‐induced dependence, 6β‐naltrexol caused significantly reduced withdrawal jumping compared to naloxone and naltrexone, at doses effective in blocking morphine antinociception. This supports the hypothesis that naloxone‐induced withdrawal symptoms result at least in part from suppression of basal signaling activity of MOR in morphine‐dependent animals. Neutral antagonists have promise in treatment of narcotic addiction.
- 1 June 2001
- Published by Springer Nature in AAPS PharmSci
- Vol. 3 (2) , 25-42
Evolutionary relationships among G protein-coupled receptors using a clustered database approach
Guanine nucleotide-binding proteincoupled receptors (GPCRs) comprise large and diverse gene families in fungi, plants, and the animal kingdom. GPCRs appear to share a common structure with 7 transmembrane segments, but sequence similarity is minimal among the most distant GPCRs. To reevaluate the question of evolutionary relationships among the disparate GPCR families, this study takes advantage of the dramatically increased number of cloned GPCRs. Sequences were selected from the National Center for Biotechnology Information (NCBI) nonredundant peptide database using iterative BLAST (Basic Local Alignment Search Tool) searches to yield a database of ∼1700 GPCRs and unrelated membrane proteins as controls, divided into 34 distinet clusters. For each cluster, separate position-specific matrices were established to optimize sequence comparisons among GPCRs. This approach resulted in significant alignments between distant GPCR families, including receptors for the biogenic amine/peptide, VIP/secretin, cAMP, STE3/MAP3 fungal pheromones, latrophilin, developmental receptors frizzled and smoothened, as well as the more distant metabotrobic glutamate receptors, the STE2/MAM2 fungal pheromone receptors, and GPR1, a fungal glucose receptor. On the other hand, alignment scores between these recognized GPCR clades with p40 (putative GPCR) and pml (putative GPCR), as well as bacteriorhodopsins, failed to support a finding of homology. This study provides a refined view of GPCR ancestry and serves as a reference database with hyperlinks to other sources. Moreover, it may facilitate database annotation and the assignment of orphan receptors to GPCR families.
- 1 June 2001
- Published by Springer Nature in AAPS PharmSci
- Vol. 3 (2) , 25-42
Evolutionary relationships among G protein-coupled receptors using a clustered database approach
Guanine nucleotide-binding proteincoupled receptors (GPCRs) comprise large and diverse gene families in fungi, plants, and the animal kingdom. GPCRs appear to share a common structure with 7 transmembrane segments, but sequence similarity is minimal among the most distant GPCRs. To reevaluate the question of evolutionary relationships among the disparate GPCR families, this study takes advantage of the dramatically increased number of cloned GPCRs. Sequences were selected from the National Center for Biotechnology Information (NCBI) nonredundant peptide database using iterative BLAST (Basic Local Alignment Search Tool) searches to yield a database of ∼1700 GPCRs and unrelated membrane proteins as controls, divided into 34 distinet clusters. For each cluster, separate position-specific matrices were established to optimize sequence comparisons among GPCRs. This approach resulted in significant alignments between distant GPCR families, including receptors for the biogenic amine/peptide, VIP/secretin, cAMP, STE3/MAP3 fungal pheromones, latrophilin, developmental receptors frizzled and smoothened, as well as the more distant metabotrobic glutamate receptors, the STE2/MAM2 fungal pheromone receptors, and GPR1, a fungal glucose receptor. On the other hand, alignment scores between these recognized GPCR clades with p40 (putative GPCR) and pml (putative GPCR), as well as bacteriorhodopsins, failed to support a finding of homology. This study provides a refined view of GPCR ancestry and serves as a reference database with hyperlinks to other sources. Moreover, it may facilitate database annotation and the assignment of orphan receptors to GPCR families.
- 1 June 2000
- Published by Springer Nature in AAPS PharmSci
- Vol. 2 (2) , 76-97
Human proton/oligopeptide transporter (POT) genes: Identification of putative human genes using bioinformatics
The proton-dependent oligopeptide transporters (POT) gene family currently consists of approximately 70 cloned cDNAs derived from diverse organisms. In mammals, two genes encoding peptide transporters, PepT1 and PepT2 have been cloned in several species including humans, in addition to a rat histidine/peptide transporter (rPHT1). Because the Candida elegans genome contains five putative POT genes, we searched the available protein and nucleic acid databases for additional mammalian/human POT genes, using iterative BLAST runs and the human expressed sequence tags (EST) database. The apparent human orthologue of rPHT1 (expression largely confined to rat brain and retina) was represented by numerous ESTs originating from many tissues. Assembly of these ESTs resulted in a contiguous sequence covering approximately 95% of the suspected coding region. The contig sequences and analyses revealed the presence of several possible splice variants of hPHT1. A second closely related human EST-contig displayed high identity to a recently cloned mouse cDNA encoding cyclic adenosine monophosphate (cAMP)-inducible 1 protein (gi:4580995). This contig served to identify a PAC clone containing deduced exons and introns of the likely human orthologue (termed hPHT2). Northern analyses with EST clones indicated that hPHT1 is primarily expressed in skeletal muscle and spleen, whereas hPHT2 is found in spleen, placenta, lung, leukocytes, and heart. These results suggest considerable complexity of the human POT gene family, with relevance to the absorption and distribution of cephalosporins and other peptoid drugs.
- 1 June 2000
- Published by Springer Nature in AAPS PharmSci
- Vol. 2 (2) , 76-97
Human proton/oligopeptide transporter (POT) genes: Identification of putative human genes using bioinformatics
The proton-dependent oligopeptide transporters (POT) gene family currently consists of approximately 70 cloned cDNAs derived from diverse organisms. In mammals, two genes encoding peptide transporters, PepT1 and PepT2 have been cloned in several species including humans, in addition to a rat histidine/peptide transporter (rPHT1). Because the Candida elegans genome contains five putative POT genes, we searched the available protein and nucleic acid databases for additional mammalian/human POT genes, using iterative BLAST runs and the human expressed sequence tags (EST) database. The apparent human orthologue of rPHT1 (expression largely confined to rat brain and retina) was represented by numerous ESTs originating from many tissues. Assembly of these ESTs resulted in a contiguous sequence covering approximately 95% of the suspected coding region. The contig sequences and analyses revealed the presence of several possible splice variants of hPHT1. A second closely related human EST-contig displayed high identity to a recently cloned mouse cDNA encoding cyclic adenosine monophosphate (cAMP)-inducible 1 protein (gi:4580995). This contig served to identify a PAC clone containing deduced exons and introns of the likely human orthologue (termed hPHT2). Northern analyses with EST clones indicated that hPHT1 is primarily expressed in skeletal muscle and spleen, whereas hPHT2 is found in spleen, placenta, lung, leukocytes, and heart. These results suggest considerable complexity of the human POT gene family, with relevance to the absorption and distribution of cephalosporins and other peptoid drugs.
- 1 April 2000
- Published by Wiley in Journal of Neurochemistry
- Vol. 74 (4) , 1418-1425
Nuclear Ca2+/Calmodulin Translocation Activated by μ‐Opioid(OP3) Receptor
Previous evidence has suggested a role for calmodulin (CaM) in opioid receptor signaling. We demonstrate here that morphine stimulation of the μ‐opioid (OP3) receptor causes rapid CaM translocation to the nucleus in OP3‐transfected human embryonic kidney (HEK)‐293 cells and in SH‐SY5Y human neuroblastoma cells. Ca2+ influx into the cells resulting from OP3 receptor activation was required for nuclear CaM translocation. Moreover, in HEK‐OP3 and SH‐SY5Y cells, increased nuclear CaM content was associated with enhanced phosphorylation of the nuclear transcription factor cyclic AMP‐responsive element‐binding protein. This appeared to be mediated by Ca2+/CaM kinases and also by a pathway involving protein kinase C. CaM was previously shown to bind directly to the OP3 receptor and to be released from the plasma membrane on agonist stimulation. To test whether OP3‐mediated CaM release contributes to nuclear CaM signaling, we used a mutant OP3 receptor (K273A) with reduced affinity for CaM that fails to release CaM from the plasma membrane. K273A‐OP3 activated Ca2+ influx to a similar extent as wild‐type OP3; however, CaM translocation to the nucleus was attenuated. These results indicate that OP3‐stimulated Ca2+ influx results in nuclear CaM translocation, which appears to be enhanced by simultaneous CaM release by OP3 wild‐type receptor from plasma membranes. These results suggest a novel Ca2+/CaM signaling pathway of opioid receptors in the regulation of transcriptional activity.
- 1 April 2000
- Published by Wiley in Journal of Neurochemistry
- Vol. 74 (4) , 1418-1425
Nuclear Ca2+/Calmodulin Translocation Activated by μ‐Opioid(OP3) Receptor
Previous evidence has suggested a role for calmodulin (CaM) in opioid receptor signaling. We demonstrate here that morphine stimulation of the μ‐opioid (OP3) receptor causes rapid CaM translocation to the nucleus in OP3‐transfected human embryonic kidney (HEK)‐293 cells and in SH‐SY5Y human neuroblastoma cells. Ca2+ influx into the cells resulting from OP3 receptor activation was required for nuclear CaM translocation. Moreover, in HEK‐OP3 and SH‐SY5Y cells, increased nuclear CaM content was associated with enhanced phosphorylation of the nuclear transcription factor cyclic AMP‐responsive element‐binding protein. This appeared to be mediated by Ca2+/CaM kinases and also by a pathway involving protein kinase C. CaM was previously shown to bind directly to the OP3 receptor and to be released from the plasma membrane on agonist stimulation. To test whether OP3‐mediated CaM release contributes to nuclear CaM signaling, we used a mutant OP3 receptor (K273A) with reduced affinity for CaM that fails to release CaM from the plasma membrane. K273A‐OP3 activated Ca2+ influx to a similar extent as wild‐type OP3; however, CaM translocation to the nucleus was attenuated. These results indicate that OP3‐stimulated Ca2+ influx results in nuclear CaM translocation, which appears to be enhanced by simultaneous CaM release by OP3 wild‐type receptor from plasma membranes. These results suggest a novel Ca2+/CaM signaling pathway of opioid receptors in the regulation of transcriptional activity.
- 1 March 2000
- Published by Springer Nature in AAPS PharmSci
- Vol. 2 (1) , 29-41
Pharmacogenomics: The promise of personalized medicine
Pharmacogenetics and pharmacogenomics deal with the genetic basis underlying variable drug response in individual patients. The traditional pharmacogenetic approach relies on studying sequence...
- 1 March 2000
- Published by Springer Nature in AAPS PharmSci
- Vol. 2 (1) , 29-41
Pharmacogenomics: The promise of personalized medicine
Pharmacogenetics and pharmacogenomics deal with the genetic basis underlying variable drug response in individual patients. The traditional pharmacogenetic approach relies on studying sequence...
- 1 January 2000
- Published by Elsevier in Journal of Neuroscience Methods
- Vol. 94 (2) , 217-225
Basal signaling activity of human dopamine D2L receptor demonstrated with an ecdysone-inducible mammalian expression system
- 1 January 2000
- Published by Elsevier in Journal of Neuroscience Methods
- Vol. 94 (2) , 217-225
Basal signaling activity of human dopamine D2L receptor demonstrated with an ecdysone-inducible mammalian expression system
Pharmacogenomics
We all differ in our response to drug treatment—occasionally with dramatic effects The era of “one drug fits all patients” is about to give way to individualised therapy matching the patient's unique genetic make up with an optimally effective drug.1 Pharmacogenetics and pharmacogenomics are the emerging disciplines that are leading the way towards individualised medicine. 2 3 Initially, researchers focused their attention on pharmacogenetics—variations in single candidate genes responsible for variable drug response. Subsequently, studies involving the entire human genome broadened the scope of investigation, giving rise to pharmacogenomics as one of the “hottest” fields in biotechnology today. #### Summary points Response to drug treatment can vary greatly between patients; genetic factors have a major role in treatment outcome Pharmacogenetics and pharmacogenomics are emerging disciplines that focus on genetic determinants of drug response at the levels of single genes or the entire human genome respectively Technologies involving gene chip arrays can determine thousands of variations in DNA sequences for individual patients; most variants are single nucleotide polymorphisms Pharmacogenomics aims at establishing a signature of DNA sequence variants that are characteristic of individual patients to assess disease susceptibility and select the optimal drug treatment This approach has the potential to revolutionise prevention and treatment of diseases Unexpected drug reactions have been noted for some time, but the systematic study of hereditary origins began only in the 1950s. A few patients developed prolonged respiratory muscular paralysis after being given succinylcholine (suxamethonium), a short acting muscle relaxant widely used in surgery and electroshock treatment. In the 1970s, a trial with the antihypertensive agent debrisoquine resulted in a precipitous drop of blood pressure and collapse in nearly 10% of volunteers. Furthermore, isoniazid therapy for tuberculosis caused peripheral neuropathies in patients who were sensitive to the neurotoxic effects of the drug. Ground breaking genetic and biochemical studies …
Pharmacogenomics
We all differ in our response to drug treatment—occasionally with dramatic effects The era of “one drug fits all patients” is about to give way to individualised therapy matching the patient's unique genetic make up with an optimally effective drug.1 Pharmacogenetics and pharmacogenomics are the emerging disciplines that are leading the way towards individualised medicine. 2 3 Initially, researchers focused their attention on pharmacogenetics—variations in single candidate genes responsible for variable drug response. Subsequently, studies involving the entire human genome broadened the scope of investigation, giving rise to pharmacogenomics as one of the “hottest” fields in biotechnology today. #### Summary points Response to drug treatment can vary greatly between patients; genetic factors have a major role in treatment outcome Pharmacogenetics and pharmacogenomics are emerging disciplines that focus on genetic determinants of drug response at the levels of single genes or the entire human genome respectively Technologies involving gene chip arrays can determine thousands of variations in DNA sequences for individual patients; most variants are single nucleotide polymorphisms Pharmacogenomics aims at establishing a signature of DNA sequence variants that are characteristic of individual patients to assess disease susceptibility and select the optimal drug treatment This approach has the potential to revolutionise prevention and treatment of diseases Unexpected drug reactions have been noted for some time, but the systematic study of hereditary origins began only in the 1950s. A few patients developed prolonged respiratory muscular paralysis after being given succinylcholine (suxamethonium), a short acting muscle relaxant widely used in surgery and electroshock treatment. In the 1970s, a trial with the antihypertensive agent debrisoquine resulted in a precipitous drop of blood pressure and collapse in nearly 10% of volunteers. Furthermore, isoniazid therapy for tuberculosis caused peripheral neuropathies in patients who were sensitive to the neurotoxic effects of the drug. Ground breaking genetic and biochemical studies …